What is Zag Bio?
Zag Bio, headquartered in San Francisco, California, is at the forefront of oncology innovation, pioneering a novel platform technology that utilizes genetically modified bacteria to selectively target and destroy solid tumors. This approach aims to overcome the limitations of traditional immunotherapies by releasing therapeutic payloads directly at the tumor site, minimizing systemic exposure and activating the immune system for a dual mechanism of action. The company's lead therapeutic candidate is designed to address the significant challenge of treating solid tumors, which represent the majority of cancer cases. Zag Bio's engineered bacteria are programmed to colonize the tumor microenvironment, creating a new frontier in living therapeutics that can adapt to the tumor's conditions.
How much funding has Zag Bio raised?
Zag Bio has raised a total of $80M across 1 funding round:
Series A
$80M
Series A (2025): $80M with participation from ABBVIE, Sanofi, JDRF T1D Fund, Polaris Partners, and Regeneron Pharmaceuticals
Key Investors in Zag Bio
ABBVIE
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges, with a focus on immunology, oncology, and neuroscience.
Sanofi
Sanofi is a global biopharmaceutical company focused on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing resources for growth and fostering innovation.
What's next for Zag Bio?
With this major strategic investment, Zag Bio is poised to accelerate its development pipeline. The substantial capital will likely fuel the advancement of its lead programs through preclinical stages and towards critical clinical trials. This funding round signals strong investor confidence in Zag Bio's unique synthetic biology and microbial engineering approach to cancer treatment, positioning the company to potentially offer new therapeutic options for patients with hard-to-treat solid tumors where current treatments have shown limited efficacy.
See full Zag Bio company page
